ECSCRI

Congratulations to ECSCRI's Dr Toby Phesse who has been awarded major funding from PCUK, with Prof. Karl Willert (University California San Diego) to determine the therapeutic benefit of a new drug targeting FZD7 in advanced prostate cancer. @CUBiosciences @CUBLSResearch @theWCRC

Latest paper from Parry (ECSCRI) and Dyson (Swansea University) highlighting key considerations for modelling gut:bacteria interactions with organoids.@CUBLSResearch @CUBiosciences @theWCRC @MDPIOpenAccess @CRUKCymru

On Monday the Phesse lab attended the WntUK conference in Oxford, with PhD student Kieran Hodson winning the Best Poster Prize. L-R Jess Hembrough, Toby Phesse, Kieran Hodson, Will Humphrey. See lnkd.in/etFBRpzY

ECSCRI welcomes Breast Cancer Now staff, patients & fundraisers, and members of the Welsh Senedd to learn about the latest breast cancer research at ECSCRI. @CUBiosciences @CUBLSResearch @theWCRC @BreastCancerNow @SeneddWales @seneddhealth

Latest research from ECSCRI @cardiffuni @theWCRC @CUBiosciences @CUBLSResearch

Congratulations to the Alan Clarke Travel Award recipients 2024 @cardiffuni @theWCRC @CUBiosciences @CUBLSResearch

Hi everyone, due to an organisational change this acoount is no longer monitored. Please follow us at @ECSCRI

Pancreatic cancer often develops without symptoms, making it difficult to diagnose. We hope that by understanding the biology of how this disease starts, this will bring about new strategies to detect cancer in the early stages. cardiff.ac.uk/news/view/2538… @amserjustintime

Only 7% of people with #pancreaticcancer survive more than five years. New research from Cardiff University is helping to expand the knowledge of this form of cancer, with the hopes of informing developments of new treatments. cardiff.ac.uk/news/view/2538…